These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
423 related articles for article (PubMed ID: 16466315)
1. Dopamine agonists in the treatment of Parkinson's disease. Bonuccelli U; Pavese N Expert Rev Neurother; 2006 Jan; 6(1):81-9. PubMed ID: 16466315 [TBL] [Abstract][Full Text] [Related]
2. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists. Kondo T J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060 [TBL] [Abstract][Full Text] [Related]
3. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment]. Jost WH; Klasser M; Reichmann H Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504 [TBL] [Abstract][Full Text] [Related]
4. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease. Chen JJ; Obering C Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444 [TBL] [Abstract][Full Text] [Related]
10. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis. Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614 [TBL] [Abstract][Full Text] [Related]
11. [Advances in the medical treatment of Parkinson's disease]. Chaná P Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S22-5. PubMed ID: 20082996 [TBL] [Abstract][Full Text] [Related]
12. Drug selection and timing of initiation of treatment in early Parkinson's disease. Schapira AH; Olanow CW Ann Neurol; 2008 Dec; 64 Suppl 2():S47-55. PubMed ID: 19127579 [TBL] [Abstract][Full Text] [Related]
13. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease. Di Rosa AE; Epifanio A; Antonini A; Stocchi F; Martino G; Di Blasi L; Tetto A; Basile G; Imbesi D; La Spina P; Di Raimondo G; Morgante L Neurol Sci; 2003 Oct; 24(3):174-5. PubMed ID: 14598073 [TBL] [Abstract][Full Text] [Related]
14. Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis. Baker WL; Silver D; White CM; Kluger J; Aberle J; Patel AA; Coleman CI Parkinsonism Relat Disord; 2009 May; 15(4):287-94. PubMed ID: 18774743 [TBL] [Abstract][Full Text] [Related]
15. A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease. Ceravolo R; Rossi C; Del Prete E; Bonuccelli U Expert Opin Drug Saf; 2016; 15(2):181-98. PubMed ID: 26646536 [TBL] [Abstract][Full Text] [Related]
16. Treatment of levodopa-induced motor complications. Stocchi F; Tagliati M; Olanow CW Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681 [TBL] [Abstract][Full Text] [Related]
17. Dopamine receptor agonists in the treatment of advanced Parkinson's disease. Stocchi F Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S54-7. PubMed ID: 20123558 [TBL] [Abstract][Full Text] [Related]
18. Neuroprotection by dopamine agonists. Lange KW; Rausch WD; Gsell W; Naumann M; Oestreicher E; Riederer P J Neural Transm Suppl; 1994; 43():183-201. PubMed ID: 7884400 [TBL] [Abstract][Full Text] [Related]
19. Role of dopamine agonists in Parkinson's disease: an update. Bonuccelli U; Pavese N Expert Rev Neurother; 2007 Oct; 7(10):1391-9. PubMed ID: 17939774 [TBL] [Abstract][Full Text] [Related]
20. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease. Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]